Frost & Sullivan releases the 'Market Research Report on Interventional Embolization Therapy'

Interventional embolization, as a minimally invasive technique that precisely delivers embolic materials through catheters to occlude target blood vessels, is playing an increasingly important role in the field of tumor treatment. With continuous advancements in medical technology and the deep development of precision medicine concepts, this technique is expanding from traditional solid tumor treatment to a wider range of indications, including hemorrhagic diseases, hyperthyroidism, and various other conditions. The industry is undergoing an iterative upgrade from traditional embolic particles to high-performance embolic microspheres. Innovative products such as drug-loaded microspheres and radioactive microspheres are emerging continuously, not only achieving precise embolization of blood vessels but also continuously releasing therapeutic drugs locally at the lesion site as drug carriers, significantly enhancing treatment outcomes. Driven by the wave of domestic substitution, domestic enterprises are accelerating technological innovation and product upgrading to continuously meet diverse clinical needs. With the intensification of population aging and patients' acceptance of minimally invasive treatments, interventional embolization is expected to go further on the path of personalized and precision medicine, providing more patients with safe and effective treatment options. In May 2025, Frost & Sullivan released the 'Interventional Embolization Market Research Report'.